JPWO2020006233A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020006233A5
JPWO2020006233A5 JP2020571855A JP2020571855A JPWO2020006233A5 JP WO2020006233 A5 JPWO2020006233 A5 JP WO2020006233A5 JP 2020571855 A JP2020571855 A JP 2020571855A JP 2020571855 A JP2020571855 A JP 2020571855A JP WO2020006233 A5 JPWO2020006233 A5 JP WO2020006233A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
pharmaceutically acceptable
stereoisomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571855A
Other languages
English (en)
Japanese (ja)
Other versions
JP7328263B2 (ja
JP2021530453A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039509 external-priority patent/WO2020006233A1/en
Publication of JP2021530453A publication Critical patent/JP2021530453A/ja
Publication of JPWO2020006233A5 publication Critical patent/JPWO2020006233A5/ja
Priority to JP2023126807A priority Critical patent/JP2023145694A/ja
Application granted granted Critical
Publication of JP7328263B2 publication Critical patent/JP7328263B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571855A 2018-06-29 2019-06-27 免疫調節化合物 Active JP7328263B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023126807A JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692176P 2018-06-29 2018-06-29
US62/692,176 2018-06-29
PCT/US2019/039509 WO2020006233A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023126807A Division JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Publications (3)

Publication Number Publication Date
JP2021530453A JP2021530453A (ja) 2021-11-11
JPWO2020006233A5 true JPWO2020006233A5 (enExample) 2022-07-05
JP7328263B2 JP7328263B2 (ja) 2023-08-16

Family

ID=68987232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571855A Active JP7328263B2 (ja) 2018-06-29 2019-06-27 免疫調節化合物
JP2023126807A Pending JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023126807A Pending JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Country Status (8)

Country Link
US (1) US12234220B2 (enExample)
EP (1) EP3814330A4 (enExample)
JP (2) JP7328263B2 (enExample)
KR (1) KR102834593B1 (enExample)
CN (1) CN113166100A (enExample)
AU (1) AU2019293235B2 (enExample)
CA (1) CA3102212A1 (enExample)
WO (1) WO2020006233A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN113166100A (zh) * 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
AU2020392427B2 (en) * 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
IL293530A (en) 2019-12-18 2022-08-01 Novartis Ag Derivatives of 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione and their uses
WO2022255889A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
AR126052A1 (es) 2021-06-03 2023-09-06 Novartis Ag Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos
IL319458A (en) 2022-09-09 2025-05-01 Innovo Therapeutics Inc Compounds that reduce ck1α and dual ck1α/gspt1
CN116655595A (zh) * 2023-06-05 2023-08-29 中国人民解放军军事科学院军事医学研究院 2,6-哌啶二酮衍生物及其制备和用途
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
CA3017740A1 (en) 2016-03-16 2017-09-21 Pearlie BURNETTE Small molecules against cereblon to enhance effector t cell function
EP3455219A4 (en) * 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CN113166100A (zh) * 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物

Similar Documents

Publication Publication Date Title
JPWO2020006264A5 (enExample)
JPWO2020006233A5 (enExample)
US10265281B2 (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
JP2021191784A5 (enExample)
JPWO2022002237A5 (enExample)
RU2017143776A (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
JP2017510610A5 (enExample)
JP2020097577A5 (enExample)
JP2010540555A5 (enExample)
JP2020510085A5 (enExample)
CN111727059A (zh) 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法
JPWO2020175629A5 (enExample)
JP2020504156A5 (enExample)
JP2025060958A5 (enExample)
Hamze How do we improve histone deacetylase inhibitor drug discovery?
JP2022169780A5 (enExample)
WO2019023667A1 (en) METHODS OF TREATING MYELODYSPLASTIC SYNDROME
JP2019524888A5 (enExample)
JPWO2022192781A5 (enExample)
JPWO2020006312A5 (enExample)
JPWO2023064282A5 (enExample)
JPWO2023129909A5 (enExample)
JPWO2022214869A5 (enExample)
JPWO2023006893A5 (enExample)
JPWO2020103859A5 (enExample)